Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication
Source: SeekingAlpha
2026-01-30 13:33:33 ET
More on Incyte, MacroGenics
- What Investors Should Know Before Buying Incyte
- Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Incyte: Buy For The Turnaround, Stay For The Pipeline
- Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy
- Incyte Japan gains approval for Minjuvi with rituximab and lenalidomide to treat relapsed follicular lymphoma
Read the full article on Seeking Alpha
For further details see:
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication
MacroGenics Inc.
NASDAQ: MGNX
MGNX Trading
2.1% G/L:
$2.185 Last:
471,219 Volume:
$2.11 Open:
MGNX Latest News
February 23, 2026 06:14:00 pm
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
November 25, 2025 04:05:00 pm
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
November 12, 2025 04:01:00 pm
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
MGNX Stock Data
$110,069,846
55,034,923
1.49%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
